Playing Russian Roulette With Tyrosine Kinase Inhibitors
- 18 December 2012
- journal article
- Published by Springer Science and Business Media LLC in Clinical Pharmacology & Therapeutics
- Vol. 93 (3), 242-244
- https://doi.org/10.1038/clpt.2012.245
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upLeukemia, 2012
- Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phaseEuropean Journal of Clinical Pharmacology, 2011
- Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology ProductsClinical Cancer Research, 2010
- Food and Oral Antineoplastics: More Than Meets the EyeClinical Cancer Research, 2010
- Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor NilotinibClinical Pharmacology & Therapeutics, 2009